Inhibikase Therapeutics logo

Inhibikase Therapeutics Share Price Today

(NASDAQ: IKT)

Inhibikase Therapeutics share price is $2.23 & ₹193.94 as on 6 Mar 2025, 2.30 'hrs' IST

$2.23

0.03

(1.36%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Inhibikase Therapeutics share price in Dollar and Rupees. Guide to invest in Inhibikase Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Inhibikase Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Inhibikase Therapeutics share price movements

  • Today's Low: $2.17
    Today's High: $2.50

    Day's Volatility :13.2%

  • 52 Weeks Low: $1.12
    52 Weeks High: $4.20

    52 Weeks Volatility :73.33%

Inhibikase Therapeutics (IKT) Returns

PeriodInhibikase Therapeutics IncIndex (Russel 2000)
3 Months
-18.32%
0.0%
6 Months
63.97%
0.0%
1 Year
-7.47%
0.0%
3 Years
-65.26%
-11.6%

Inhibikase Therapeutics (IKT) Key Statistics

in dollars & INR

Previous Close
$2.2
Open
$2.21
Today's High
$2.5
Today's Low
$2.17
Market Capitalization
$159.9M
Today's Volume
$117.7K
52 Week High
$4.2
52 Week Low
$1.12
Revenue TTM
$1.0
EBITDA
$-20.0M
Earnings Per Share (EPS)
$-3.01
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-270.1%

How to invest in Inhibikase Therapeutics Stock (IKT) from India?

It is very easy for Indian residents to invest directly in Inhibikase Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Inhibikase Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Inhibikase Therapeutics or IKT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Inhibikase Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Inhibikase Therapeutics shares which would translate to 0.390 fractional shares of Inhibikase Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Inhibikase Therapeutics, in just a few clicks!

Returns in Inhibikase Therapeutics (IKT) for Indian investors in Rupees

The Inhibikase Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Inhibikase Therapeutics investment value today

Current value as on today

₹97,480

Returns

₹2,520

(-2.52%)

Returns from Inhibikase Therapeutics Stock

₹7,469 (-7.47%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Inhibikase Therapeutics (IKT)

-46%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Inhibikase Therapeutics Stock from India on INDmoney has decreased by -46% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Inhibikase Therapeutics

  • Sands Capital Ventures, LLC

    15.07%

  • Soleus Capital Management, L.P.

    8.70%

  • Fairmount Funds Management LLC

    8.43%

  • Perceptive Advisors LLC

    8.15%

  • COMMODORE CAPITAL LP

    8.15%

  • ADAR1 Capital Management LLC

    7.02%

Analyst Recommendation on Inhibikase Therapeutics

Buy

    83%Buy

    16%Hold

    0%Sell

Based on 6 Wall street analysts offering stock ratings for Inhibikase Therapeutics(by analysts ranked 0 to 5 stars)

Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
5
4
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Inhibikase Therapeutics Stock (IKT)

What analysts predicted

Upside of 258.74%

Target:

$8.00

Current:

$2.23

Insights on Inhibikase Therapeutics Stock (Ticker Symbol: IKT)

  • Price Movement

    In the last 6 months, IKT stock has moved up by 66.4%
  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 116.41K → 1.0 (in $), with an average decrease of 65.8% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -4.17M → -5.77M (in $), with an average decrease of 11.5% per quarter
  • IKT vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 74.0%
  • IKT vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 117.5%

Inhibikase Therapeutics Technicals Summary

Sell

Neutral

Buy

Inhibikase Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Inhibikase Therapeutics (IKT) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Inhibikase Therapeutics Inc logo
-1.76%
63.97%
-7.47%
-65.26%
-96.25%
Regeneron Pharmaceuticals, Inc. logo
-1.42%
-40.28%
-29.31%
11.08%
44.83%
Beone Medicines Ltd logo
17.63%
36.87%
64.37%
45.89%
71.3%
Vertex Pharmaceuticals Incorporated logo
1.94%
4.92%
19.37%
108.73%
123.83%
Alnylam Pharmaceuticals, Inc. logo
-8.03%
-0.89%
66.53%
52.9%
126.66%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Inhibikase Therapeutics Inc logo
NA
NA
NA
0.0
-2.7
-1.13
NA
-0.07
Regeneron Pharmaceuticals, Inc. logo
17.86
17.86
1.01
43.09
0.16
0.07
0.01
273.57
Beone Medicines Ltd logo
NA
NA
NA
1.43
-0.19
-0.06
NA
31.22
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.34
18.07
-0.03
0.13
NA
63.87
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
0.57
-15.01
-0.03
NA
0.52
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Inhibikase Therapeutics Inc logo
Buy
$159.9M
-96.25%
NA
0.0%
Regeneron Pharmaceuticals, Inc. logo
Buy
$73.8B
44.83%
17.86
31.07%
Beone Medicines Ltd logo
NA
$29.1B
71.3%
NA
-16.92%
Vertex Pharmaceuticals Incorporated logo
Buy
$124.9B
123.83%
32.84
-4.86%
Alnylam Pharmaceuticals, Inc. logo
Buy
$31.4B
126.66%
NA
-12.37%

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Organization
Inhibikase Therapeutics
Employees
8
CEO
Mr. Mark T. Iwicki
Industry
Health Technology

Management People of Inhibikase Therapeutics

NameTitle
Mr. Mark T. Iwicki
Chief Executive Officer
Dr. Christopher H. Cabell FACC, M.D., MHS
President and Head of Research & Development
Mr. Garth Lees-Rolfe CPA
Chief Financial Officer
Dr. John Adams Ph.D.
Chief Scientific Officer
Dr. Surendra Singh Ph.D.
Head of Chemistry, Manufacturing & Controls

Important FAQs about investing in IKT Stock from India :

What is Inhibikase Therapeutics share price today?

Inhibikase Therapeutics share price today stands at $2.23, Open: $2.21 ; Previous Close: $2.20 ; High: $2.50 ; Low: $2.17 ; 52 Week High: $4.20 ; 52 Week Low: $1.12.

The stock opens at $2.21, after a previous close of $2.20. The stock reached a daily high of $2.50 and a low of $2.17, with a 52-week high of $4.20 and a 52-week low of $1.12.

Can Indians buy Inhibikase Therapeutics shares?

Yes, Indians can invest in the Inhibikase Therapeutics (IKT) from India.

With INDmoney, you can buy Inhibikase Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Inhibikase Therapeutics at zero transaction cost.

How can I buy Inhibikase Therapeutics shares from India?

It is very easy to buy Inhibikase Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Inhibikase Therapeutics (IKT) be purchased?

Yes, you can buy fractional shares of Inhibikase Therapeutics with INDmoney app.

What are the documents required to start investing in Inhibikase Therapeutics stocks?

To start investing in Inhibikase Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Inhibikase Therapeutics Stock (IKT)?

Today’s highest price of Inhibikase Therapeutics (IKT) is $2.50.

Today’s lowest price of Inhibikase Therapeutics (IKT) is $2.17.

What is today's market capitalisation of Inhibikase Therapeutics?

Today's market capitalisation of Inhibikase Therapeutics IKT is 159.9M

What is the 52 Week High and Low Range of Inhibikase Therapeutics Stock (IKT)?

  • 52 Week High

    $4.20

  • 52 Week Low

    $1.12

What are the historical returns of Inhibikase Therapeutics (IKT)?

  • 1 Month Returns

    -1.76%

  • 3 Months Returns

    63.97%

  • 1 Year Returns

    -7.47%

  • 5 Years Returns

    -96.25%

Who is the Chief Executive Officer (CEO) of Inhibikase Therapeutics ?

Mr. Mark T. Iwicki is the current Chief Executive Officer (CEO) of Inhibikase Therapeutics.